Biotechnology
Compare Stocks
5 / 10Stock Comparison
RADX vs RNW vs CWEN vs BEP vs NEE
Revenue, margins, valuation, and 5-year total return — side by side.
Renewable Utilities
Renewable Utilities
Renewable Utilities
Regulated Electric
RADX vs RNW vs CWEN vs BEP vs NEE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Biotechnology | Renewable Utilities | Renewable Utilities | Renewable Utilities | Regulated Electric |
| Market Cap | $33M | $1.33B | $7.84B | $10.57B | $194.60B |
| Revenue (TTM) | $4M | $129.66B | $1.43B | $6.43B | $27.93B |
| Net Income (TTM) | $-38M | $11.97B | $169M | $212M | $8.18B |
| Gross Margin | 1.1% | 77.9% | 50.3% | 44.8% | 47.8% |
| Operating Margin | -10.5% | 48.4% | 12.0% | 13.3% | 29.5% |
| Forward P/E | — | 0.4x | 26.9x | — | 23.0x |
| Total Debt | $0.00 | $732.28B | $10.20B | $35.73B | $95.62B |
| Cash & Equiv. | $29M | $40.42B | $818M | $2.31B | $2.81B |
RADX vs RNW vs CWEN vs BEP vs NEE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Dec 24 | May 26 | Return |
|---|---|---|---|
| Radiopharm Theranos… (RADX) | 100 | 89.1 | -10.9% |
| ReNew Energy Global… (RNW) | 100 | 82.3 | -17.7% |
| Clearway Energy, In… (CWEN) | 100 | 146.8 | +46.8% |
| Brookfield Renewabl… (BEP) | 100 | 149.3 | +49.3% |
| NextEra Energy, Inc. (NEE) | 100 | 129.9 | +29.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RADX vs RNW vs CWEN vs BEP vs NEE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
RADX ranks third and is worth considering specifically for growth exposure.
- Rev growth 11.1%, EPS growth 85.3%, 3Y rev CAGR 6.4%
- 11.1% revenue growth vs CWEN's 4.2%
RNW is the clearest fit if your priority is value.
- Lower P/E (0.4x vs 23.0x)
CWEN is the clearest fit if your priority is valuation efficiency and defensive.
- PEG 0.59 vs NEE's 1.33
- Beta 0.54, yield 7.9%, current ratio 1.13x
BEP is the #2 pick in this set and the best alternative if dividends and momentum is your priority.
- 11.7% yield, 1-year raise streak, vs NEE's 2.4%, (2 stocks pay no dividend)
- +60.8% vs RNW's -17.7%
NEE carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 30 yrs, beta 0.21, yield 2.4%
- 266.0% 10Y total return vs CWEN's 237.4%
- Lower volatility, beta 0.21, current ratio 0.60x
- 29.3% margin vs RADX's -10.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 11.1% revenue growth vs CWEN's 4.2% | |
| Value | Lower P/E (0.4x vs 23.0x) | |
| Quality / Margins | 29.3% margin vs RADX's -10.6% | |
| Stability / Safety | Beta 0.21 vs RADX's 0.88 | |
| Dividends | 11.7% yield, 1-year raise streak, vs NEE's 2.4%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +60.8% vs RNW's -17.7% | |
| Efficiency (ROA) | 3.9% ROA vs RADX's -48.4%, ROIC 4.1% vs -254.1% |
RADX vs RNW vs CWEN vs BEP vs NEE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
RADX vs RNW vs CWEN vs BEP vs NEE — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
RNW leads in 2 of 6 categories
CWEN leads 1 • RADX leads 0 • BEP leads 0 • NEE leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
RNW leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
RNW is the larger business by revenue, generating $129.7B annually — 35684.8x RADX's $4M. NEE is the more profitable business, keeping 29.3% of every revenue dollar as net income compared to RADX's -10.6%. On growth, RNW holds the edge at +37.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $4M | $129.7B | $1.4B | $6.4B | $27.9B |
| EBITDAEarnings before interest/tax | — | $86.9B | $1.0B | $3.3B | $15.5B |
| Net IncomeAfter-tax profit | — | $12.0B | $169M | $212M | $8.2B |
| Free Cash FlowCash after capex | — | -$23.8B | $268M | -$8.3B | -$3.8B |
| Gross MarginGross profit ÷ Revenue | +1.1% | +77.9% | +50.3% | +44.8% | +47.8% |
| Operating MarginEBIT ÷ Revenue | -10.5% | +48.4% | +12.0% | +13.3% | +29.5% |
| Net MarginNet income ÷ Revenue | -10.6% | +9.2% | +11.8% | +3.3% | +29.3% |
| FCF MarginFCF ÷ Revenue | -10.1% | -18.4% | +18.8% | -128.7% | -13.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +37.2% | +21.1% | +9.1% | +7.3% |
| EPS Growth (YoY)Latest quarter vs prior year | — | +94.8% | -35.3% | +25.3% | +160.0% |
Valuation Metrics
RNW leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 26.9x trailing earnings, CWEN trades at a 43% valuation discount to RNW's 46.9x P/E. Adjusting for growth (PEG ratio), CWEN offers better value at 0.59x vs NEE's 1.64x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $33M | $1.3B | $7.8B | $10.6B | $194.6B |
| Enterprise ValueMkt cap + debt − cash | $12M | $8.6B | $17.2B | $44.0B | $287.4B |
| Trailing P/EPrice ÷ TTM EPS | -1.08x | 46.91x | 26.86x | -512.46x | 28.36x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 0.41x | — | — | 23.02x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.59x | — | 1.64x |
| EV / EBITDAEnterprise value multiple | — | 11.27x | 16.23x | 13.18x | 18.73x |
| Price / SalesMarket cap ÷ Revenue | 12.42x | 1.30x | 5.48x | 1.62x | 7.08x |
| Price / BookPrice ÷ Book value/share | 0.93x | 1.43x | 0.77x | 0.28x | 2.93x |
| Price / FCFMarket cap ÷ FCF | — | — | 21.24x | — | — |
Profitability & Efficiency
Evenly matched — RNW and NEE each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
NEE delivers a 12.7% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-109 for RADX. BEP carries lower financial leverage with a 1.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to RNW's 5.59x. On the Piotroski fundamental quality scale (0–9), BEP scores 5/9 vs CWEN's 4/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -109.2% | +8.4% | +3.0% | +0.6% | +12.7% |
| ROA (TTM)Return on assets | -48.4% | +1.2% | +1.1% | +0.2% | +3.9% |
| ROICReturn on invested capital | -2.5% | +4.9% | +0.9% | +0.9% | +4.1% |
| ROCEReturn on capital employed | -60.6% | +6.9% | +1.2% | +1.1% | +4.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 | 4 | 5 | 5 |
| Debt / EquityFinancial leverage | — | 5.59x | 1.72x | 1.02x | 1.44x |
| Net DebtTotal debt minus cash | -$29M | $691.9B | $9.4B | $33.4B | $92.8B |
| Cash & Equiv.Liquid assets | $29M | $40.4B | $818M | $2.3B | $2.8B |
| Total DebtShort + long-term debt | $0 | $732.3B | $10.2B | $35.7B | $95.6B |
| Interest CoverageEBIT ÷ Interest expense | -584.59x | 86.76x | 0.55x | 1.04x | 1.99x |
Total Returns (Dividends Reinvested)
CWEN leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CWEN five years ago would be worth $17,246 today (with dividends reinvested), compared to $2,349 for RADX. Over the past 12 months, BEP leads with a +60.8% total return vs RNW's -17.7%. The 3-year compound annual growth rate (CAGR) favors CWEN at 12.8% vs RADX's -38.3% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -19.6% | -7.8% | +13.7% | +25.1% | +16.1% |
| 1-Year ReturnPast 12 months | -4.4% | -17.7% | +39.6% | +60.8% | +42.0% |
| 3-Year ReturnCumulative with dividends | -76.5% | +4.4% | +43.5% | +23.4% | +31.0% |
| 5-Year ReturnCumulative with dividends | -76.5% | -45.7% | +72.5% | +12.6% | +38.2% |
| 10-Year ReturnCumulative with dividends | -76.5% | -50.5% | +237.4% | +199.1% | +266.0% |
| CAGR (3Y)Annualised 3-year return | -38.3% | +1.5% | +12.8% | +7.3% | +9.4% |
Risk & Volatility
Evenly matched — BEP and NEE each lead in 1 of 2 comparable metrics.
Risk & Volatility
NEE is the less volatile stock with a 0.21 beta — it tends to amplify market swings less than RADX's 0.88 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BEP currently trades 96.0% from its 52-week high vs RADX's 25.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.80x | 0.69x | 0.55x | 0.89x | 0.19x |
| 52-Week HighHighest price in past year | $16.25 | $8.24 | $41.54 | $35.97 | $98.75 |
| 52-Week LowLowest price in past year | $3.62 | $4.38 | $27.67 | $22.27 | $63.88 |
| % of 52W HighCurrent price vs 52-week peak | +25.5% | +65.5% | +91.8% | +96.0% | +94.5% |
| RSI (14)Momentum oscillator 0–100 | 41.3 | 64.1 | 45.9 | 57.2 | 54.3 |
| Avg Volume (50D)Average daily shares traded | 184K | 734K | 828K | 875K | 8.7M |
Analyst Outlook
Evenly matched — BEP and NEE each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: RNW as "Buy", CWEN as "Buy", BEP as "Buy", NEE as "Buy". Consensus price targets imply 20.7% upside for RNW (target: $7) vs 3.7% for BEP (target: $36). For income investors, BEP offers the higher dividend yield at 11.70% vs NEE's 2.40%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $6.52 | $43.67 | $35.83 | $99.11 |
| # AnalystsCovering analysts | — | 6 | 16 | 20 | 36 |
| Dividend YieldAnnual dividend ÷ price | — | — | +7.9% | +11.7% | +2.4% |
| Dividend StreakConsecutive years of raises | — | 1 | 2 | 1 | 30 |
| Dividend / ShareAnnual DPS | — | — | $3.01 | $4.04 | $2.24 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
RNW leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). CWEN leads in 1 (Total Returns). 3 tied.
RADX vs RNW vs CWEN vs BEP vs NEE: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is RADX or RNW or CWEN or BEP or NEE a better buy right now?
For growth investors, Radiopharm Theranostics Limited (RADX) is the stronger pick with 1114% revenue growth year-over-year, versus 4.
2% for Clearway Energy, Inc. (CWEN). Clearway Energy, Inc. (CWEN) offers the better valuation at 26. 9x trailing P/E, making it the more compelling value choice. Analysts rate ReNew Energy Global Plc (RNW) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — RADX or RNW or CWEN or BEP or NEE?
On trailing P/E, Clearway Energy, Inc.
(CWEN) is the cheapest at 26. 9x versus ReNew Energy Global Plc at 46. 9x. On forward P/E, ReNew Energy Global Plc is actually cheaper at 0. 4x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — RADX or RNW or CWEN or BEP or NEE?
Over the past 5 years, Clearway Energy, Inc.
(CWEN) delivered a total return of +72. 5%, compared to -76. 5% for Radiopharm Theranostics Limited (RADX). Over 10 years, the gap is even starker: NEE returned +265. 3% versus RADX's -77. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — RADX or RNW or CWEN or BEP or NEE?
By beta (market sensitivity over 5 years), NextEra Energy, Inc.
(NEE) is the lower-risk stock at 0. 19β versus Brookfield Renewable Partners L. P. 's 0. 89β — meaning BEP is approximately 372% more volatile than NEE relative to the S&P 500. On balance sheet safety, Brookfield Renewable Partners L. P. (BEP) carries a lower debt/equity ratio of 102% versus 6% for ReNew Energy Global Plc — giving it more financial flexibility in a downturn.
05Which is growing faster — RADX or RNW or CWEN or BEP or NEE?
By revenue growth (latest reported year), Radiopharm Theranostics Limited (RADX) is pulling ahead at 1114% versus 4.
2% for Clearway Energy, Inc. (CWEN). On earnings-per-share growth, the picture is similar: Brookfield Renewable Partners L. P. grew EPS 92. 4% year-over-year, compared to -2. 4% for NextEra Energy, Inc.. Over a 3-year CAGR, RADX leads at 643. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — RADX or RNW or CWEN or BEP or NEE?
NextEra Energy, Inc.
(NEE) is the more profitable company, earning 24. 9% net margin versus -1055. 3% for Radiopharm Theranostics Limited — meaning it keeps 24. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RNW leads at 53. 5% versus -1050. 6% for RADX. At the gross margin level — before operating expenses — RNW leads at 91. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is RADX or RNW or CWEN or BEP or NEE more undervalued right now?
On forward earnings alone, ReNew Energy Global Plc (RNW) trades at 0.
4x forward P/E versus 23. 0x for NextEra Energy, Inc. — 22. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RNW: 20. 7% to $6. 52.
08Which pays a better dividend — RADX or RNW or CWEN or BEP or NEE?
In this comparison, BEP (11.
7% yield), CWEN (7. 9% yield), NEE (2. 4% yield) pay a dividend. RADX, RNW do not pay a meaningful dividend and should not be held primarily for income.
09Is RADX or RNW or CWEN or BEP or NEE better for a retirement portfolio?
For long-horizon retirement investors, NextEra Energy, Inc.
(NEE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 19), 2. 4% yield, +265. 3% 10Y return). Both have compounded well over 10 years (NEE: +265. 3%, RADX: -77. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between RADX and RNW and CWEN and BEP and NEE?
These companies operate in different sectors (RADX (Healthcare) and RNW (Utilities) and CWEN (Utilities) and BEP (Utilities) and NEE (Utilities)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: RADX is a small-cap high-growth stock; RNW is a small-cap high-growth stock; CWEN is a small-cap income-oriented stock; BEP is a mid-cap income-oriented stock; NEE is a mid-cap quality compounder stock. CWEN, BEP, NEE pay a dividend while RADX, RNW do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.